Hitoshi Asakura
Niigata University
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Hitoshi Asakura.
Journal of Clinical Investigation | 1999
Masako Murai; Hiroyuki Yoneyama; Akihisa Harada; Zhang Yi; Christian Vestergaard; Baoyu Guo; Kenji Suzuki; Hitoshi Asakura; Kouji Matsushima
We examined the molecular pathogenesis of graft-versus-host disease-associated (GVHD-associated) liver injury in mice, focusing on the role of chemokines. At the second week after cell transfer in the parent-into-F1 model of GVHD, CD8(+) T cells -- especially donor-derived CD8(+) T cells -- infiltrated the liver, causing both portal hepatitis and nonsuppurative destructive cholangitis (NSDC). These migrating cells expressed CCR5. Moreover, macrophage inflammatory protein-1alpha (MIP-1alpha), one of the ligands for CCR5, was selectively expressed on intralobular bile duct epithelial cells, endothelial cells, and infiltrating macrophages and lymphocytes. Administration of anti-CCR5 antibody dramatically reduced the infiltration of CCR5(+)CD8(+) T lymphocytes into the liver, and consequently protected against liver damage in GVHD. The levels of Fas ligand (FasL) mRNA expression in the liver were also decreased by anti-CCR5 antibody treatment. Anti-MIP-1alpha antibody treatment also reduced liver injury. These results suggest that MIP-1alpha-induced migration of CCR5-expressing CD8(+) T cells into the portal areas of the liver plays a significant role in causing liver injury in GVHD; thus, CCR5 and its ligand may be the novel target molecules of therapeutic intervention of hepatic GVHD.
Nature Immunology | 2003
Masako Murai; Hiroyuki Yoneyama; Taichi Ezaki; Makoto Suematsu; Yuya Terashima; Akihisa Harada; Hiromasa Hamada; Hitoshi Asakura; Hiromichi Ishikawa; Kouji Matsushima
Acute graft-versus-host disease (a-GVHD) is initiated primarily by immunologically competent cytotoxic T cells (CTLs) that express anti-host specificities. However, the host lymphoid compartment in which these precursor CTLs are initially stimulated remains unclear. Here we show that gut Peyers patches (PPs) are required to activate anti-host CTL responses in a well characterized murine acute graft-versus-host reaction (a-GVHR) model, involving transfer of parent lymphocytes into F1 hybrid recipients. The a-GVHR was prevented when recruitment of donor T cells into PP was interrupted either by disrupting the gene encoding chemokine receptor CCR5 or by blocking integrin α4β7–MAdCAM-1 (mucosal vascular addressin) interactions. Mice deficient for PPs failed to develop a-GVHD in two models of disease induction. Thus, blockade of CTL generation in PPs might offer new strategies for circumventing a-GVHD.
Gastroenterology | 1999
Yasunobu Matsuda; Takafumi Ichida; Jun Matsuzawa; Kazuhito Sugimura; Hitoshi Asakura
Abstract Background & Aims: The molecular status of the p16 INK4 tumor-suppressor gene has not been fully elucidated in hepatocellular carcinoma. The aim of this study was to clarify the mechanism that gives rise to inactivation of p16 INK4 in hepatocellular carcinoma. Methods: The status of p16 INK4 was evaluated in 60 hepatocellular carcinomas by immunohistochemical staining, differential polymerase chain reaction, single-strand conformational polymorphism, methylation-specific polymerase chain reaction, and methylation-sensitive single nucleotide primer extension. Results: Immunohistochemical staining showed that 29 of the 60 tumors exhibited complete loss of p16 INK4 expression. High levels of DNA methylation were detected in 24 of 29 cases of hepatocellular carcinoma with negative p16 INK4 expression, with methylation of 60%–85% of the CpG islands. In contrast, the level of methylation was p16 INK4 staining, and no methylation was detected in tumors with positive immunostaining. Intragenic alteration of p16 INK4 was detected in 4 cases. Conclusions: A strong correlation was found between the extent of methylation and the degree of expression of p16 INK4 in tumor tissues, indicating that epigenetic change due to extensive CpG methylation is the main cause of inactivation of p16 INK4 in hepatocellular carcinoma. GASTROENTEROLOGY 1999;116:394-400
Current Pharmaceutical Design | 2003
Koji Sawada; Tetsuichiro Muto; Takashi Shimoyama; Masamichi Satomi; Toshio Sawada; Hirokazu Nagawa; Nobuo Hiwatashi; Hitoshi Asakura; Toshifumi Hibi
The administration of steroids is not always effective for the treatment of ulcerative colitis (UC). Their long-term use often causes adverse effects which sometimes result in their stoppage and acute exacerbation. Therefore, an alternative treatment is necessary in order to decrease steroid dosage and avoid the clinical problems associated with steroids. Methods The effectiveness and adverse effects of a leukocytapheresis (LCAP) were investigated in a controlled multicenter trial with randomized assignment of 76 active-stage UC patients in two groups. In the LCAP group (39 patients), LCAP weekly for 5 weeks as an intensive therapy was added to the on-going drug therapy, while steroids were maintained but not increased, and then LCAP was gradually reduced to once every 4 weeks as a maintenance therapy. In the high dose prednisolone (h-PSL) group (37 patients), PSL was added or increased 30 approximately 40 mg/day for moderately severe and 60 approximately 80 mg/day for severe patients and then gradually tapered. Findings The LCAP group showed a significantly higher effectiveness (74% vs. 38%; p=0.005) and lower incidence of adverse effects (24% vs. 68%; p<0.001). The patients were able to continue the trial for a longer period in the LCAP group than the h-PSL group (p=0.012). Clinical activity and endoscopic indexes showed the LCAP group had better improvements than the h-PSL group. Interpretation The results of the trial show that LCAP permits a reduction in total PSL dosage and is more effective and safer than high-dose PSL administration for intensive therapy, and LCAP may maintain remission longer than PSL.
Journal of Experimental Medicine | 2002
Hiroyuki Yoneyama; Shosaku Narumi; Yanyun Zhang; Masako Murai; Marco Baggiolini; Antonio Lanzavecchia; Takafumi Ichida; Hitoshi Asakura; Kouji Matsushima
Various immune diseases are considered to be regulated by the balance of T helper (Th)1 and Th2 subsets. Although Th lymphocytes are believed to be generated in draining lymph nodes (LNs), in vivo Th cell behaviors during Th1/Th2 polarization are largely unexplored. Using a murine granulomatous liver disease model induced by Propionibacterium acnes, we show that retention of Th1 cells in the LNs is controlled by a chemokine, CXCL10/interferon (IFN) inducible protein 10 produced by mature dendritic cells (DCs). Hepatic LN DCs preferentially produced CXCL10 to attract 5′-bromo-2′-deoxyuridine (BrdU)+CD4+ T cells and form clusters with IFN-γ–producing CD4+ T cells by day 7 after antigen challenge. Blockade of CXCL10 dramatically altered the distribution of cluster-forming BrdU+CD4+ T cells. BrdU+CD4+ T cells in the hepatic LNs were selectively diminished while those in the circulation were significantly increased by treatment with anti-CXCL10 monoclonal antibody. This was accompanied by accelerated infiltration of memory T cells into the periphery of hepatic granuloma sites, most of them were in cell cycle and further produced higher amount of IFN-γ leading to exacerbation of liver injury. Thus, mature DC-derived CXCL10 is pivotal to retain Th1 lymphocytes within T cell areas of draining LNs and optimize the Th1-mediated immune responses.
Journal of Clinical Investigation | 1998
Hiroyuki Yoneyama; Akihisa Harada; Toshio Imai; Masataka Baba; Osamu Yoshie; Yi Zhang; Hidemitsu Higashi; Masako Murai; Hitoshi Asakura; Kouji Matsushima
Thymus and activation-regulated chemokine (TARC) is a recently identified lymphocyte-directed CC chemokine which specifically chemoattracts T helper type 2 CD4(+) T cells in human. To establish the pathophysiological roles of TARC in vivo, we investigated whether a monoclonal antibody (mAb) against TARC could inhibit the induction of hepatic lesions in murine model using Propionibacterium acnes and lipopolysaccharide (LPS). P. acnes-induced intrahepatic granuloma formation in the priming phase is essential to the subsequent liver injury elicited by a low dose of LPS. The priming phase appears to be dominated by Th1 type immune responses determined by the profile of chemokine and chemokine receptor expression. TARC was selectively produced by granuloma-forming cells, and CC chemokine receptor 4 (CCR4)-expressing CD4(+) T cells migrated into the liver after LPS administration. In vivo injection of anti-TARC mAb just before LPS administration protected the mice from acute lethal liver damage, which was accompanied by a significant reduction of both CCR4 mRNA expression and IL-4 production by liver-infiltrating CD4(+) T cells. Moreover, both TNF-alpha and Fas ligand expressions in the liver were decreased by anti-TARC treatment. These results suggest that recruitment of IL-4-producing CCR4(+) CD4(+) T cells by granuloma-derived TARC into the liver parenchyma may be a key cause of massive liver injury after systemic LPS administration.
Journal of Gastroenterology | 2002
Osamu Kanauchi; Toshihiro Suga; Masahiro Tochihara; Toshifumi Hibi; Makoto Naganuma; Hitoshi Asakura; Hiroshi Nakano; Kazuya Takahama; Yoshihide Fujiyama; Akira Andoh; Takashi Shimoyama; Nobuyuki Hida; Ken Haruma; Hideki Koga; Keiichi Mitsuyama; Michio Sata; Masanobu Fukuda; Atsushi Kojima; Tadao Bamba
Background. Germinated barley foodstuff (GBF) is a prebiotic foodstuff that effectively increases luminal butyrate production by stimulating the growth of protective bacteria. In the first pilot study, GBF has been shown to reduce both clinical activity and mucosal inflammation in ulcerative colitis (UC). The aim of this study was to investigate the efficacy of GBF in the treatment of UC in a multicenter open control trial. Methods. Eighteen patients with mildly to moderately active UC were divided into two groups using a random allocation protocol. The control group (n = 7) were given a baseline anti-inflammatory therapy for 4 weeks. In the GBF-treated group (n = 11), patients received 20–30 g GBF daily, together with the baseline treatment, for 4 weeks. The response to the treatments was evaluated clinically and endoscopically. Fecal micro-flora were also analyzed. Results. After 4 weeks of observation, the GBF-treated group showed a significant decrease in clinical activity index scores compared with the control group (P < 0.05). No side effects related to GBF were observed. GBF therapy increased fecal concentrations of Bifidobacterium and Eubacterium limosum. Conclusions. Oral GBF therapy may have the potency to reduce clinical activity of UC. We believe that these results support the use of GBF administration as a new adjunct therapy for UC.
Gastroenterology | 1982
Hitoshi Asakura; Masaharu Tsuchiya; Sadakazu Aiso; Mamoru Watanabe; Kensuke Kobayashi; Toshifumi Hibi; Koshi Ando; Hajime Takata; Susumu Sekiguchi
The frequency deviation of human lymphocyte-DR antigens as well as human lymphocyte A, B, and C antigens was assessed in 40 Japanese patients with ulcerative colitis and compared with 51 ethnically matched healthy Japanese. The antigen that was of significantly higher frequency in patients with ulcerative colitis was HLA-DR2. This antigen was found in 70% of the patients vs. 31% of controls [chi 2 = 13.4, p less than 0.001, corrected p less than 0.01, relative risk = 5.1). In addition, an increased frequency of HLA-B5-DR2, which is the most common haplotype in Japanese populations, was found in 55% of the patients with ulcerative colitis compared with 22% of the controls (chi 2 = 10.84, p less than 0.001).
Cancer | 1998
Yuhsaku Mita; Yutaka Aoyagi; Masahiko Yanagi; Takeshi Suda; Yasufumi Suzuki; Hitoshi Asakura
Measurements of serum concentrations of des‐γ‐carboxy prothrombin (DCP) are widely used for diagnosing hepatocellular carcinoma (HCC). However, the DCP is not always sensitive enough to detect small HCCs. In the current study, the authors investigated the usefulness of DCP in the early diagnosis of HCC, using a more sensitive enzyme immunoassay than is conventionally employed.
British Journal of Cancer | 2000
Masaaki Kobayashi; Terasu Honma; Yasunobu Matsuda; Yutaka Suzuki; Rintarou Narisawa; Youichi Ajioka; Hitoshi Asakura
Post-translational stabilization of beta-catenin through mutation of the adenomatous polyposis coli (APC) gene has been proposed as an early step in colorectal carcinogenesis. Beta-catenin may translocate from the cytoplasm to the nucleus, where it might serve as a transcriptional factor to stimulate tumour formation. We investigated intracellular localization of beta-catenin in sporadic colorectal adenomas and cancers as well as familial adenomatous polyposis (FAP). Nuclear over-expression of beta-catenin was observed in 35% (7/20) of intramucosal cancers and 42% (23/55) of invasive cancers but was not seen in any adenomas from sporadic or FAP cases. Cytoplasmic beta-catenin in adenomas was significantly higher than that of normal mucosa in both sporadic and FAP cases. The cytoplasmic intensity index of cancers was significantly higher than that of sporadic adenomas, but the index was not correlated with nuclear expression in cancers. These findings suggest that nuclear translocation of beta-catenin is involved in development of intramucosal cancer rather than adenoma, independent of APC mutations. Cytoplasmic accumulation of beta-catenin may occur in adenomas, but it remains to be determined whether this is a cause or a consequence of colorectal cancer.